Fabrication of fMW@TiO2@MoS2-Sm2S3/GCE electrochemical nanosensor for simultaneous measurement of sertraline and buspirone neuroleptic drugs

•Synthesis and characterization of fMW@TiO2@MoS2-Sm2S3 nanocomposite.•Simultaneous quantification of Sertraline and Buspirone by fMW@TiO2@MoS2-Sm2S3/GCE.•Obtaining maximum current densities based on response surface methodology.•Advantages of stability, repeatability and reproducibility of the nanosensor.•Good capability of nanosensor for determination of SRT and BPH in the human plasma. In this paper for the first time, due to the importance of simultaneous administration of sertraline (SRT) and buspirone (BPH), a sensitive electrochemical nanosensor was fabricated and used for simultaneous measurement of them. Firstly, fMW@TiO2@MoS2-Sm2S3 was synthesized and characterized by different techniques. The performance of fMW@TiO2@MoS2-Sm2S3/GCE nanocomposite was investigated for simultaneous quantifications of SRT and BPH using different electrochemical methods. Response surface methodology (RSM) indicated that pH 7.0 for phosphate buffer solutions (PBS), scan rate of 0.08 V s-1, accumulation potential of 0.4 V and accumulation time of 125 s in CHA get maximum anodic currents. The anodic peak current densities of SRT and BPH drugs were improved excellently on the surface of fMW@TiO2@MoS2-Sm2S3/GCE compared to bare GCE. With the DPV method, the linear response 1.53–38.46, 38.46–74.07 µM and 1.11–29.12, 29.12–90.90 µM were obtained for SRT and BPH, respectively. Also, the detection limit of 0.50 µM and 0.36 µM were acquired for SRT and BPH, respectively. The catalytic rate constants were calculated to be 3.63 × 107 and 2.80 × 107 cm3 mol-1 s-1 for SRT and BPH, respectively. The practical application of the fMW@TiO2@MoS2-Sm2S3 for measurements of the SRT and BPH in human plasma and tablets showed good recovery percentage. [Display omitted]